[AZN] Astrazeneca PLC

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NYSE

The data is delayed by 15 minutes.

 

Price: 27.31 Change: 0.14 (0.5%)
Ext. hours: Change: 0 (0%)

chart AZN

Refresh chart

Strongest Trends Summary For AZN

AZN is in the long-term up 50% in 4 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: AstraZeneca PLC is engaged in the discovery, development, and commercialization of medicines for cardiovascular and metabolic disease; oncology; respiratory, inflammation, and autoimmunity; and infection, neuroscience, and gastrointestinal disease areas worldwide. Its principal products include Crestor for the treatment of dyslipidaemia and hypercholesterolemia; Seloken/Toprol-XL for control of hypertension and for use in heart failure and angina; Iressa for non-small cell lung cancer; Faslodex for breast cancer in post-menopausal women; and Zoladex for prostate cancer, breast cancer, and certain benign gynaecological disorders. The company's principal products also comprise Pulmicort for treating asthma and chronic obstructive pulmonary disease (COPD); Symbicort for maintenance treatment of asthma and COPD; Nexium for treatment of acid-related diseases; Seroquel XR for the treatment of schizophrenia, bipolar disorder, major depressive disorder, and generalised anxiety disorder; and Synagis for the prevention

Fundamental Ratios
Shares Outstanding EPS3.52 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y156.85% Sales Growth - 4 Quarters Sales Growth - Q/Q P/E9.81
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA ROE ROI
Current Ratio Quick Ratio Long Term Debt/Equity Debt Ratio
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities-2.39 B Cash From Investing Activities-1.23 B Cash From Operating Activities1.01 B Gross Profit5.3 B
Net Profit697 M Operating Profit923 M Total Assets55.17 B Total Current Assets13.81 B
Total Current Liabilities16.15 B Total Debt11.01 B Total Liabilities36.89 B Total Revenue6.31 B
Technical Data
High 52 week43.02 Low 52 week32.97 Last close37.78 Last change-0.05%
RSI45.85 Average true range0.63 Beta0.64 Volume2.88 M
Simple moving average 20 days-0.78% Simple moving average 50 days-5.71% Simple moving average 200 days-2.2%
Performance Data
Performance Week0.35% Performance Month-2.55% Performance Quart-5.56% Performance Half0.08%
Performance Year11.61% Performance Year-to-date-5.24% Volatility daily1.11% Volatility weekly2.47%
Volatility monthly5.07% Volatility yearly17.55% Relative Volume389.21% Average Volume5.47 M
New High New Low

News

2019-09-20 11:54:03 | FibroGen's Evrenzo Gets Nod in Japan for Anemia with CKD

2019-09-20 08:41:12 | Pharma Stock Roundup: FDA Approves Expanded Use of MRK/J&J's Drugs & Other Updates

2019-09-19 14:31:06 | Ironwood Amends Linzess Agreement with AstraZeneca in China

2019-09-19 12:46:00 | U.K. stocks snap three-day losing run

2019-09-16 10:43:02 | AstraZeneca's Farxiga Gets Fast Track Tag for Heart Failure

2019-09-16 10:16:02 | Biogen Stops Late-Stage Studies on Alzheimer's Candidate

2019-09-16 08:33:12 | Breast Cancer Drugs May Inflame Lungs Per FDA Safety Alert

2019-09-16 07:30:00 | FDA Grants Fast Track Designation for FARXIGA in Heart Failure

2019-09-16 03:23:23 | AstraZeneca diabetes drug granted fast track status for heart failure treatment

2019-09-13 10:08:02 | Glaxo's Asthma Drug Nucala Gets FDA Nod for Pediatric Use

2019-09-13 09:46:01 | Pharma Stock Roundup: Pipeline/Regulatory Updates From GSK, PFE & Others

2019-09-13 04:47:08 | Roche Reports Positive Data on Tecentriq & NMOSD Drug Revised

2019-09-12 17:46:53 | Gilead Tops List of Most Innovative Drug Companies

2019-09-12 09:09:01 | Roche RHHBY Reports Positive Data on Tecentriq & MS Drug

2019-09-11 17:47:02 | East Bay company eyes first drug approval after decade-long journey

2019-09-11 15:50:48 | Leaner Pfizer Positioned to Boost R&D Output

2019-09-11 11:40:03 | AVEO Surges on Favorable Updated OS Results on RCC Drug

2019-09-11 11:13:03 | Bristol-Myers' BMY Opdivo Shows Long-Term Survival Benefit

2019-09-11 09:46:01 | Lexicon LXRX Settles With Sanofi for $260M, Shares Rally

2019-09-11 09:32:01 | 4 Big Drugmakers Boasting Impressive Oncology Pipelines

2019-09-11 08:57:04 | Should You Buy AstraZeneca PLC LON:AZN For Its Dividend?

2019-09-10 11:41:03 | ACADIA Surges on Early Success of Nuplazid Dementia Study

2019-09-09 21:32:48 | AstraZeneca's Executive VP Sees Upside, As China's Government Speeds Up New Drug Approval

2019-09-09 07:00:00 | IMFINZI Is First Immunotherapy to Show Both Significant Survival Benefit and Improved, Durable Responses in Extensive-Stage Small Cell Lung Cancer

2019-09-09 03:38:00 | CORRECTED-AstraZeneca's Imfinzi prolongs survival in aggressive lung cancer

2019-09-06 11:48:03 | Novartis' Capmatinib Gets Breakthrough Therapy Tag From FDA

2019-09-06 11:36:03 | Pharma Stock Roundup: AGN's Opioid Settlement, Line Extension Nod in EU for MRK, JNJ Drugs

2019-09-06 08:39:12 | Roche's Tecentriq Combo Gets EU Nod for Difficult Lung Cancer

2019-09-05 13:50:05 | AstraZeneca's Tagrisso Gets Nod in China for First-Line NSCLC

2019-09-05 12:52:00 | Podcast: Why Big Pharma Is Betting on a New Biotech Therapy

2019-09-05 11:12:00 | Is the FDA Out to Get This $2.9 Billion Diabetes Drug Class?

2019-09-04 10:32:02 | Vertex VRTX Inks All-Cash Deal to Acquire Semma for $950M

2019-09-03 15:05:15 | 5 things to know ahead of Viela Bio’s planned $150M IPO

2019-09-03 10:44:53 | Companies to Watch: Roche gets more time for Spark deal, AstraZeneca shows promise in clinical trial, Snap get upgraded

2019-09-03 10:26:04 | Companies to Watch: Roche gets more time for Spark deal, AstraZeneca shows promise in clinical trial, Snap get upgraded

2019-09-02 15:13:16 | The Week Ahead In Biotech: Cardiology, Analyst Conferences In The Spotlight

2019-09-02 07:30:00 | Pound tumbles as British factory output hits seven-year low ahead of Brexit showdown

2019-08-30 14:56:02 | Md. biotech files to go public with $150M offering

2019-08-30 13:50:19 | AstraZeneca Spin-Off Viela Bio Files For IPO

2019-08-30 11:16:03 | AstraZeneca's Lupus Drug Meets Primary Endpoint in Study

2019-08-30 10:11:02 | Pharma Stock Roundup: JNJ's Opioid Lawsuit, Regulatory Nod for LLY, BMY, RHHBY Drugs

2019-08-29 09:06:01 | Forget Pfizer, Add These Big Drugmakers to Your Portfolio

2019-08-28 10:21:02 | AstraZeneca's Fasenra Gets Orphan Drug Status for New Disease

2019-08-28 10:18:05 | AstraZeneca respiratory business gets boost from 3-drug inhaler results

2019-08-28 10:10:02 | Here's Why Merck MRK is Outperforming Its Industry Of Late

2019-08-28 07:00:00 | PT010 Phase III ETHOS trial met its primary endpoint in chronic obstructive pulmonary disease

2019-08-28 03:13:21 | UPDATE 2-AstraZeneca respiratory business gets boost from 3-drug inhaler results

2019-08-27 14:46:04 | Viela Bio clears another hurdle to get rare disease drug to market

2019-08-27 11:32:03 | AstraZeneca's Farxiga Gets Fast Track Tag for Renal Outcome

2019-08-27 07:00:00 | FDA Grants Fast Track Designation for FARXIGA in Chronic Kidney Disease